An ongoing dialogue on HIV/AIDS, infectious diseases,
September 18th, 2009
Integrase Inhibitors: In Search of an Abbreviation
The alphabet soup that characterizes HIV therapeutics has always been one of its quirky challenges — for example, who could possibly know that 3TC, CBV, TZV, EPZ, and LAM all refer to drugs that are (or contain) lamivudine?
This drives our ID fellows nuts, and is certainly a strong deterrent to non-HIV specialists to learning the field.
(Maybe that’s why they pay us the big bucks… oh wait.)
And while we’ve grown comfortable with the abbreviations for the 3 oldest drug classes — NRTI, NNRTI, and PI — what are we to do with integrase inhibitors? Some candidates:
- “II” — sounds funny when you say it (“eye-eye”), and could be confused with “eleven” depending on the font
- “INSTI” — for “integrase strand transfer inhibitor”; I’ve already seen this one around a lot, but have also seen it written “InSTI” (lower-case n), which is hard to type
- “INI” — for “INtegrase Inhibitor”; same upper vs lower-case issue as “INSTI”, and saying “INI” always has an anatomic (especially umbilical) connotation to it
Still not sure where we’ll end up with this one, but I suspect “INSTI” will rule the day.
Comments are closed.
Paul E. Sax, MD
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
- Observations from ID and Beyond: Mayo Clinic Study on Paxlovid Outcomes Is Reassuring — But Likely Underestimates Rebound Rate
- Are HIV Integrase Inhibitors Associated with Cardiovascular Disease?
- What Are the Consequences of Inappropriate Antibiotic Prescribing for Pediatric Outpatients?
- Comprehensive Evaluation Couldn't Find Cause of Long Covid Symptoms
- NAAT-Positive/Toxin-Negative C. difficile: To Treat or Not to Treat?
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball CDC C diff COVID-19 CROI cure darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster